Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators - McDonald criteria - Document - PDFSEARCH.IO

First Page		Document Content
Autoimmune diseases Medicine Immunosuppressants Neurological disorders Treatment of multiple sclerosis Glatiramer acetate Natalizumab Mitoxantrone Fingolimod Multiple sclerosis Immunology Immune system		Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators Add to Reading List Source URL: www.hsc.nihr.ac.uk Download Document from Source Website File Size: 144,21 KB Share Document on Facebook

	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qn6Z - View Document
	Stellungnahme der AkdÄ zur Nutzenbewertung von Fingolimod (neues Anwendungsgebiet) DocID: 1n48S - View Document
	Rote-Hand-Brief zu Gilenya® (Fingolimod) DocID: 1h06f - View Document
	Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators DocID: 1fWCE - View Document
	Bijlage bij email betreffende vergoeding fingolimod juliArtikel uit MenSen nr. 4 Samenvatting aanvullende voorwaarden zoals is overeengekomen op 4 juni 2013 met CVZ, VWS, zorgverzekeraars, MS Vereniging Nederland, DocID: 1ea9n - View Document